{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Deng Z"],"funding":["the National Key Clinical Discipline","the Guangdong Natural Science Fund for Outstanding Youth Scholars","the program of Guangdong Provincial Clinical Research Center for Digestive Diseases","the National Natural Science Foundation of China"],"pagination":["480"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12468768"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["32(9)"],"pubmed_abstract":["<b>Background:</b> The incidence of early-onset gastric cancer (EOGC) has been steadily increasing in recent years. However, the efficacy of adjuvant chemotherapy (AC) in this population remains unclear. This study aimed to investigate the clinicopathological characteristics, survival outcomes, and efficacy of AC between EOGC and average-onset gastric cancer (AOGC) patients. <b>Methods:</b> Patients with stage II-III gastric adenocarcinomas who underwent curative D2 gastrectomy at the Sixth Affiliated Hospital of Sun Yat-sen University from January 2014 to December 2021 were enrolled and classified into two groups: EOGC (≤45 years) and AOGC (>45 years) groups. Clinicopathological characteristics, overall survival (OS), and efficacy of AC were compared between the two groups. Western and Ea"],"journal":["Current oncology (Toronto, Ont.)"],"pubmed_title":["Age-Stratified Clinicopathological Features and Efficacy of Adjuvant Chemotherapy in Resectable Gastric Cancer: An East-West Population-Based Study."],"pmcid":["PMC12468768"],"funding_grant_id":["No. 2020B1515020005","2020B1111170004","No. 82070684"],"pubmed_authors":["Xiong Z","Huang D","Lian L","Guo J","Zhong B","Deng Z","Xu H","Chen S"],"additional_accession":[]},"is_claimable":false,"name":"Age-Stratified Clinicopathological Features and Efficacy of Adjuvant Chemotherapy in Resectable Gastric Cancer: An East-West Population-Based Study.","description":"<b>Background:</b> The incidence of early-onset gastric cancer (EOGC) has been steadily increasing in recent years. However, the efficacy of adjuvant chemotherapy (AC) in this population remains unclear. This study aimed to investigate the clinicopathological characteristics, survival outcomes, and efficacy of AC between EOGC and average-onset gastric cancer (AOGC) patients. <b>Methods:</b> Patients with stage II-III gastric adenocarcinomas who underwent curative D2 gastrectomy at the Sixth Affiliated Hospital of Sun Yat-sen University from January 2014 to December 2021 were enrolled and classified into two groups: EOGC (≤45 years) and AOGC (>45 years) groups. Clinicopathological characteristics, overall survival (OS), and efficacy of AC were compared between the two groups. Western and Ea","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Aug","modification":"2026-05-01T03:23:01.311Z","creation":"2026-05-01T03:11:13.492Z"},"accession":"S-EPMC12468768","cross_references":{"pubmed":["41002549"],"doi":["10.3390/curroncol32090480"]}}